Am. J. Respir. Crit. Care Med., Volume 162, Number 5, November 2000, 1752-1759

Recombinant Tissue Factor Pathway Inhibitor Reduces Lipopolysaccharide-Induced Pulmonary Vascular Injury by Inhibiting Leukocyte Activation

PERENLEI ENKHBAATAR, KENJI OKAJIMA, KAZUNORI MURAKAMI, MITSUHIRO UCHIBA, HIROAKI OKABE, KAZUTOSHI OKABE, and YASUO YAMAGUCHI

Department of Laboratory Medicine and Second Department of Surgery, Kumamoto University School of Medicine, Kumamoto, Japan

Tissue factor pathway inhibitor (TFPI) is an important physiologic inhibitor of the extrinsic pathway of the coagulation system. We investigated whether recombinant TFPI (rTFPI) could reduce pulmonary vascular injury by inhibiting leukocyte activation in rats given lipopolysaccharide (LPS). Pre- or posttreatment of animals with rTFPI significantly inhibited LPS-induced pulmonary vascular injury, as well as coagulation abnormalities. rTFPI significantly inhibited increases in lung tissue levels of tumor necrosis factor (TNF)-, cytokine-induced neutrophil chemoattractant, and myeloperoxidase. Expression of TNF- messenger RNA in the lung after LPS administration was significantly reduced by rTFPI administration. However, neither DX-9065a, a selective inhibitor of Factor Xa, nor recombinant Factor VIIa treated with dansyl-glutamylglycylarginyl-chloromethyl ketone, a selective inhibitor of Factor VIIa, had any effects on LPS-induced pulmonary vascular injury despite their potent anticoagulant effects. rTFPI significantly inhibited TNF- production by LPS-stimulated monocytes in vitro. rTFPI also significantly inhibited several formyl-Met-Leu-Phe-induced neutrophil functions, as well as increases in the expression of CD11b and CD18 on the neutrophil cell surface in vitro. Additionally, rTFPI inhibited increases in levels of intracellular calcium, a second messenger of neutrophil activation, in formyl-Met-Leu-Phe-stimulated neutrophils in vitro. These results strongly suggested that rTFPI reduces pulmonary vascular injury by inhibiting leukocyte activation, as well as coagulation abnormalities in rats given LPS.

This article has been cited by other articles:

				J. A. Bastarache, L. Wang, Z. Wang, K. H. Albertine, M. A. Matthay, and L. B. Ware Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L874 - L881. [Abstract] [Full Text] [PDF]

				M. Wygrecka, P. Markart, L. Fink, A. Guenther, and K. T Preissner Raised protein levels and altered cellular expression of factor VII activating protease (FSAP) in the lungs of patients with acute respiratory distress syndrome (ARDS) Thorax, October 1, 2007; 62(10): 880 - 888. [Abstract] [Full Text] [PDF]

				G. Choi, A. P. J. Vlaar, M. Schouten, C. van't Veer, T. van der Poll, M. Levi, and M. J. Schultz Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation Eur. Respir. J., September 1, 2007; 30(3): 423 - 428. [Abstract] [Full Text] [PDF]

				T. M. Ravindranath, M. Goto, M. Demir, M. Tobu, M. F. Kujawski, D. Hoppensteadt, V. Samonte, O. Iqbal, M. M. Sayeed, and J. Fareed Tissue Factor Pathway Inhibitor and Thrombin Activatable Fibrinolytic Inhibitor Plasma Levels following Burnand Septic Injuries in Rats Clinical and Applied Thrombosis/Hemostasis, October 1, 2004; 10(4): 379 - 385. [Abstract] [PDF]

				S. M. Opal The nexus between systemic inflammation and disordered coagulation in sepsis Innate Immunity, April 1, 2004; 10(2): 125 - 129. [Abstract] [PDF]

				K. Hahnenkamp, G. Theilmeier, H. K. Van Aken, and C. W. Hoenemann The Effects of Local Anesthetics on Perioperative Coagulation, Inflammation, and Microcirculation Anesth. Analg., June 1, 2002; 94(6): 1441 - 1447. [Full Text] [PDF]

				M. J. TOBIN Critical Care Medicine in AJRCCM 2000 Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): 1347 - 1361. [Full Text] [PDF]